In silico analysis revealed arp2/3 complex molecule as a potential prognostic and predictive biomarker in breast cancer

We can stratify breast cancer into different clinically relevant molecular subtypes. The ARPC3 molecule can significantly contribute to the process of metastasis formation due to its expression in actin cytoskeleton remodeling and has been arousing the interest of many researchers. In this work, we sought to evaluate in silica the role of ARPC3 gene expression and its correlation with prognostic and predictive factors in breast cancer, using several datasets deposited in public repositories. Our data showed that ARPC3 showed higher gene expression in breast tumor samples regardless of clinical stages compared to adjacent normal tissue. Additionally, we identified higher expression of mRNA for ARPC3 in hormone-dependent tumors and less expressed in triple negative cases. Our sample evidence allowed us to infer that there is a correlation between the differential expression of ARPC3 with lymph node status, SBR classification, molecular subtype and HER2 oncoprotein. Regarding prognosis, high expression of ARPC3 in human breast tumor samples conferred worse recurrence-free survival for patients. Finally, among patients who were diagnosed with luminal tumors and who did not respond to hormone therapy, they had higher expression of ARPC3. Together, our data point to ARPC3 as a potential prognostic and predictive biomarker in breast cancer.